HIV-Associated Pneumonia Diagnosis and Treatment

Primary Differential Diagnosis

In HIV patients with low CD4 counts presenting with pneumonia, the differential diagnosis must be stratified by CD4 level, with bacterial pneumonia remaining possible at any CD4 count, while opportunistic infections follow predictable thresholds 1
Bacterial pneumonia is the most common at any CD4 level, with Streptococcus pneumoniae and Haemophilus influenzae being common causes 2, 3
Mycobacterium tuberculosis can occur at any CD4 count, though risk increases significantly below 300 cells/μL 1

HIV-infected patients with pneumonia should receive an oral beta-lactam plus an oral macrolide as first-line empiric therapy, never macrolide monotherapy due to increased drug-resistant Streptococcus pneumoniae risk 2, 3
The preferred regimen is high-dose amoxicillin or amoxicillin-clavulanate PLUS azithromycin or clarithromycin 2, 3
For penicillin allergy or recent beta-lactam use, use respiratory fluoroquinolone (moxifloxacin, levofloxacin 750 mg/day, or gemifloxacin) 2, 3

If CD4 <200 cells/μL, consider adding trimethoprim-sulfamethoxazole (TMP-SMX) for PCP coverage 4, 1
Use fluoroquinolones with extreme caution in HIV patients, as they are active against Mycobacterium tuberculosis and monotherapy can delay TB diagnosis, promote resistance, and increase transmission risk 2, 3

Initiate TMP-SMX prophylaxis (one double-strength tablet daily) immediately if CD4 <200 cells/μL and patient is not already receiving it 4, 1
Alternative indications for PCP prophylaxis include history of oropharyngeal candidiasis, unexplained fever >100°F for ≥2 weeks 4

Start ART as soon as possible after diagnosis, ideally within 2 weeks of pneumonia diagnosis for most opportunistic infections 6
For bacterial pneumonia, start ART immediately once patient is stable 6
For PCP, start ART within 2 weeks 6
For TB with CD4 <50 cells/μL, start ART within 2 weeks of TB treatment initiation 6
For TB with CD4 ≥50 cells/μL, start ART within 2-8 weeks 6

Never use macrolide monotherapy in HIV patients due to high rates of drug-resistant S. pneumoniae 2, 3
Never use fluoroquinolone monotherapy without excluding TB, as this can mask TB and promote resistance 2, 3
Do not delay empiric bacterial coverage while waiting for diagnostic workup - treat promptly 2, 3
Do not forget to assess oxygenation via pulse oximetry or ABG in all pneumonia patients 2, 3
Do not overlook the need for PCP prophylaxis if CD4 <200 cells/μL - this prevents life-threatening disease 4, 1